These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32943323)

  • 1. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
    Jiao Y; Liu M; Luo N; Guo H; Li J
    Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
    Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
    Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report.
    Jin Y; Xiao W; Wang X; Cui Y; Li B; Liu X
    Medicine (Baltimore); 2021 Oct; 100(42):e27581. PubMed ID: 34678907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
    Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
    Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report.
    Xu L; Tao NN; Liang B; Li DW; Li HC; Su LL
    Thorac Cancer; 2022 Feb; 13(3):502-505. PubMed ID: 34953097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
    Babacan NA; Pina IB; Signorelli D; Prelaj A; Garassino MC; Tanvetyanon T
    Clin Lung Cancer; 2020 Sep; 21(5):e456-e463. PubMed ID: 32265109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
    Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H
    Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 10. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression].
    Roulleaux Dugage M; Brosseau S
    Bull Cancer; 2021 Oct; 108(10):904-906. PubMed ID: 34598788
    [No Abstract]   [Full Text] [Related]  

  • 13. Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
    Wang G; Chai Q; Xiao Y; Peng W; Teng M; Wang J; Lin H; Su X; Wu L
    Front Immunol; 2020; 11():607416. PubMed ID: 33584678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
    Rajasekaran N; Wang X; Ravindranathan S; Chin DJ; Tseng SY; Klakamp SL; Widmann K; Kapoor VN; Vexler V; Keegan P; Yao S; LaVallee T; Khare SD
    Cancer Immunol Immunother; 2024 Feb; 73(3):60. PubMed ID: 38400933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of response to PD-L1 blockade across tumor types.
    Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
    Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
    Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
    Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
    Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
    Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
    Roesel C; Kambartel K; Kopeika U; Berzins A; Voshaar T; Krbek T
    Curr Oncol; 2019 Apr; 26(2):e270-e273. PubMed ID: 31043837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.